GoldenGolden
Advanced Search
Alphamab Oncology

Alphamab Oncology

Biologics

Alphamab combines antibody discovery platforms and GMP manufacturing expertise to its pipeline of nanobodies, bispecifics and multi-antibody cocktails.

Timeline

May 28, 2019
Alphamab Oncology raises a $60,000,000 series B round.
May 28, 2019
Alphamab Oncology raises a $60,000,000 series B round.
May 2019
Alphamab Oncology raises a $60,000,000 series B round from Hudson Bay Capital.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 16, 2020
BioSpace
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug applicatio

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.